Welcome to Paid Research Studies




  • Conditions:   Head and Neck Cancer;   Hearing Disorder;   Hyperlipidemia
    Intervention:  
    Sponsor:   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified July 18, 2017

  • Conditions:   Migraine Disorders;   Photophobia;   Phonophobia;   Acute Migraine
    Interventions:   Drug: Rimegepant;   Drug: Placebo
    Sponsor:   Biohaven Pharmaceutical Holding Company Ltd.
    Recruiting - verified July 2017

  • Condition:   Hearing Loss
    Interventions:   Device: Phase I - Standard Microphone Cros Input;   Device: Phase II - Automatic directional microphone Cros Input;   Device: Phase III - No Cros Input
    Sponsor:   University of Miami
    Not yet recruiting - verified August 2017

  • Conditions:   Migraine;   Acute Migraine;   Phonophobia;   Photophobia
    Interventions:   Drug: BHV-3000;   Drug: Placebo Oral Tablet
    Sponsor:   Biohaven Pharmaceutical Holding Company Ltd.
    Recruiting - verified August 2017

  • Conditions:   Sensory Disorders;   Autism;   Autism Spectrum Disorder;   Autism With High Cognitive Abilities;   Autistic Behavior;   Hyperacusis
    Interventions:   Behavioral: Exposure therapy;   Behavioral: Psycho-education;   Behavioral: Caregiver education/home program development
    Sponsor:   University of Florida
    Not yet recruiting - verified July 2017

  • Conditions:   Hearing Loss;   Deafness
    Interventions:   Behavioral: Aural Rehabilitation Group;   Behavioral: Cognitive Training Group
    Sponsors:   Gallaudet University;   Columbia University;   The Cleveland Clinic
    Recruiting - verified May 2017

  • Conditions:   Implants, Cochlear;   Child;   Hearing Loss, Bilateral
    Intervention:   Device: Hybrid L24
    Sponsor:   Bruce J Gantz
    Recruiting - verified May 2017

  • Condition:   VNS Implanted Tinnitus Patients
    Intervention:   Device: Vagus Nerve Stimulation
    Sponsors:   The University of Texas at Dallas;   Defense Advanced Research Projects Agency
    Recruiting - verified May 2017

  • Conditions:   Usher Syndrome, Type 2A;   Retinitis Pigmentosa 39
    Intervention:  
    Sponsors:   Jaeb Center for Health Research;   Foundation Fighting Blindness;   Duke University;   Oregon Health and Science University
    Recruiting - verified June 2017

  • Conditions:   Hearing Loss;   Health Literacy
    Intervention:   Other: Health Information Assessment
    Sponsors:   University of Michigan;   Rochester Institute of Technology;   Sinai Health System;   Hurley Medical Center;   Boston University
    Recruiting - verified March 2017

  • Conditions:   Cmv Congenital;   CMV;   Congenital Cmv;   SNHL;   Sensorineural Hearing Loss
    Interventions:   Drug: Valganciclovir;   Drug: Simple Syrup
    Sponsors:   Albert Park;   National Institute on Deafness and Other Communication Disorders (NIDCD);   Genentech, Inc.
    Not yet recruiting - verified April 2017

  • Conditions:   Deafness; Sensoneural Single Sided;   Conductive Hearing Loss;   Mixed Hearing Loss
    Intervention:   Device: Osia System
    Sponsor:   Cochlear Bone Anchored Solutions
    Recruiting - verified June 2017

  • Condition:   Hearing Loss
    Intervention:   Device: PockeTalker" Hearing Assistive Device (HAD)
    Sponsor:   New York University School of Medicine
    Recruiting - verified May 2017

  • Conditions:   Congenital Fibrosis of Extraocular Muscles;   Duane Retraction Syndrome;   Duane Radial Ray Syndrome;   Mobius Syndrome;   Brown Syndrome;   Marcus Gunn Syndrome;   Strabismus Congenital;   Horizontal Gaze Palsy;   Horizontal Gaze Palsy With Progressive Scoliosis;   Facial Palsy;   Facial Paresis, Hereditary, Congenital;   Third Nerve Palsy;   Fourth Nerve Palsy;   Sixth Nerve Palsy;   Synkinesis;   Ocular Motility Disorders;   Levator-Medial Rectus Synkinesis;   Athabaskan Brainstem Dysgenesis;   Tongue Paralysis;   Ninth Nerve Disorder;   Fifth Nerve Palsy;   Seventh Nerve Palsy;   Eleventh Nerve Disorder;   Twelfth Nerve Disorder;   Vagus Nerve Paralysis;   Moebius Sequence
    Intervention:  
    Sponsors:   Boston Children’s Hospital;   Howard Hughes Medical Institute;   National Eye Institute (NEI)
    Recruiting - verified February 2017

  • Condition:   Concussion, Mild
    Intervention:   Device: Q collar
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting - verified January 2017

  • Condition:   Tinnitus
    Interventions:   Device: Desyncra;   Other: Cognitive Behavioral Therapy
    Sponsors:   VA National Center for Rehabilitative Auditory Research;   Desyncra, Inc.
    Recruiting - verified March 2017

  • Condition:   Cisplatin Induced Hearing Loss
    Intervention:   Drug: OTO-104
    Sponsor:   Otonomy, Inc.
    Recruiting - verified April 2017

  • Condition:   Hearing Loss
    Intervention:   Other: Family Medicine Hearing Loss Best Practice Alert
    Sponsor:   University of Michigan
    Recruiting - verified December 2016

  • Conditions:   Hearing Loss;   Language Development;   Social Behavior
    Interventions:   Behavioral: augmentative and alternative communication technology;   Behavioral: Usual Care
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting - verified December 2016

  • Condition:   Hearing Loss, Unilateral
    Intervention:   Device: Cochlear implant
    Sponsors:   University of North Carolina, Chapel Hill;   Med-El Corporation
    Recruiting - verified April 2017

  • Condition:   Focus of the Study is to Promote Healthy Hearing
    Interventions:   Other: Noisy City information about hearing health care;   Other: Generic Game
    Sponsors:   Photozig, Inc.;   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified October 2016

  • Conditions:   Hearing Loss;   Geriatric Disorder
    Interventions:   Other: Tele-HS;   Other: PCP encouragement
    Sponsors:   Duke University;   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified October 2016

  • Condition:   Hearing Loss, Idiopathic Sudden Sensorineural
    Interventions:   Drug: AM-111 0.4 mg/ml;   Drug: AM-111 0.8 mg/ml;   Other: Placebo
    Sponsor:   Auris Medical, Inc.
    Recruiting - verified January 2017

  • Conditions:   Wolfram Syndrome;   Diabetes Mellitus;   Optic Nerve Atrophy;   Deafness;   Diabetes Insipidus;   Ataxia
    Intervention:  
    Sponsors:   Washington University School of Medicine;   American Diabetes Association;   National Institutes of Health (NIH)
    Recruiting - verified July 2016

  • Conditions:   Wolfram Syndrome;   Diabetes Mellitus;   Optic Nerve Atrophy;   Ataxia
    Intervention:   Drug: dantrolene sodium
    Sponsor:   Washington University School of Medicine
    Recruiting - verified March 2017

  • Condition:   Tinnitus
    Interventions:   Device: Neuromonics Tinnitus Treatment Program;   Device: Placebo Device
    Sponsors:   United States Army Aeromedical Research Laboratory;   Congressionally Directed Medical Research Programs
    Recruiting - verified May 2017

  • Conditions:   Hearing Loss;   Ear Diseases;   Hearing Disorders;   Otorhinolaryngologic Diseases;   Asymmetrical Hearing Loss;   Single-Sided Deafness
    Intervention:   Device: HiResolution Bionic Cochlear Implant
    Sponsor:   Advanced Bionics
    Recruiting - verified October 2016

  • Condition:   Hearing Loss
    Interventions:   Behavioral: standard hearing aid fitting;   Behavioral: coupler-based fitting;   Behavioral: coupler-based fitting
    Sponsor:   VA Office of Research and Development
    Recruiting - verified May 2017

  • Condition:   Hearing Impairment
    Intervention:   Device: NEATCAP
    Sponsor:   University of Pittsburgh
    Recruiting - verified May 2017

  • Condition:   Sensorineural Hearing Loss, Bilateral
    Intervention:   Device: Cochlear Nucleus CI532
    Sponsor:   Cochlear
    Recruiting - verified February 2017

  • Condition:   Hearing Loss
    Interventions:   Procedure: Hum Test;   Procedure: Weber Test;   Device: Audiogram
    Sponsor:   New York University School of Medicine
    Recruiting - verified October 2016

  • Conditions:   Tinnitus;   Pulsatile Tinnitus;   Venous Sinus Stenosis;   Dural Sinus Stenosis
    Intervention:   Device: Venous Sinus Stenting
    Sponsor:   Weill Medical College of Cornell University
    Recruiting - verified January 2017

  • Condition:   Tinnitus
    Interventions:   Other: Tone;   Other: Video
    Sponsor:   University of Minnesota - Clinical and Translational Science Institute
    Not yet recruiting - verified March 2017

  • Conditions:   Articulation Disorder;   Dysarthria;   Prelingual Deafness
    Intervention:   Device: Opti-Speech
    Sponsors:   Vulintus, Inc.;   National Institute on Deafness and Other Communication Disorders (NIDCD);   Callier Center for Communication Disorders;   Cleveland Hearing and Speech Center;   Case Western Reserve University
    Recruiting - verified October 2016

  • Conditions:   Total Unilateral Deafness;   Unilateral Partial Deafness
    Intervention:   Device: Med-el MAESTRO Cochlear Implant with Flex 28 electrode array
    Sponsors:   Dr. Daniel Lee;   University of Wisconsin, Madison
    Recruiting - verified February 2017

  • Condition:   Congenital Sensorineural Deafness
    Interventions:   Behavioral: Telemedicine;   Behavioral: In-person ART
    Sponsors:   University of Colorado, Denver;   National Institute on Deafness and Other Communication Disorders (NIDCD);   University of Colorado, Boulder
    Recruiting - verified July 2017

  • Condition:   Deafness
    Intervention:   Procedure: Cochlear implant surgery
    Sponsor:   Mayo Clinic
    Recruiting - verified November 2016

  • Condition:   Tinnitus
    Intervention:   Behavioral: Cognitive behavioral therapy
    Sponsor:   University of California, Irvine
    Recruiting - verified May 2017

  • Conditions:   Type 1 Diabetes;   Diabetes Insipidus;   Diabetes Mellitus;   Wolfram Syndrome
    Intervention:  
    Sponsors:   Washington University School of Medicine;   National Institutes of Health (NIH);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified October 2016

  • Condition:   High Frequency Sensorineural Hearing Loss
    Intervention:   Device: Nucleus Hybrid L24 Implant
    Sponsor:   Cochlear
    Recruiting - verified March 2017

  • Condition:   Hearing Loss, Bilateral (Causes Other Than Tumors)
    Intervention:   Device: Nucleus ABI541 Auditory Brainstem Implant
    Sponsor:   New York University School of Medicine
    Recruiting - verified October 2016

  • Condition:   Unilateral Hearing Loss
    Intervention:   Device: Hearing aid
    Sponsor:   Massachusetts Eye and Ear Infirmary
    Recruiting - verified April 2017

  • Condition:   Tinnitus
    Interventions:   Device: noise sound stimulation (Tucker-Davis Technologies);   Device: body electrical stimulation (Digitimer device);   Device: transcranial magnetic stimulation (Magstim)
    Sponsor:   University of Minnesota - Clinical and Translational Science Institute
    Recruiting - verified March 2017

  • Conditions:   Unilateral Moderate to Profound Hearing Loss, Single-Sided Deafness (SSD);   Asymmetric Hearing Loss
    Interventions:   Device: Cochlear Implant;   Other: Control Group
    Sponsors:   University of North Carolina, Chapel Hill;   Med-El Corporation
    Recruiting - verified September 2016

  • Conditions:   Hearing Loss;   Partial Deafness;   Hearing Disorders;   Ear Diseases;   Otorhinolaryngologic Diseases
    Interventions:   Device: HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode;   Device: EAS sound processor
    Sponsor:   Advanced Bionics
    Recruiting - verified July 2017

  • Conditions:   Mucopolysaccharidosis Disorders;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Alpha-Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Glycoprotein Metabolic Disorders;   Sphingolipidoses;   Recessive Leukodystrophies;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann-Pick B;   Niemann-Pick C Subtype 2;   Sphingomyelin Deficiency;   Peroxisomal Disorders;   Adrenoleukodystrophy With Cerebral Involvement;   Zellweger Syndrome;   Neonatal Adrenoleukodystrophy;   Infantile Refsum Disease;   Acyl-CoA Oxidase Deficiency;   D-Bifunctional Enzyme Deficiency;   Multifunctional Enzyme Deficiency;   Alpha-methylacyl-CoA Racmase Deficiency;   Mitochondrial Neurogastrointestingal Encephalopathy;   Severe Osteopetrosis;   Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation);   Inherited Metabolic Disorders
    Interventions:   Biological: Stem Cell Transplantation;   Drug: IMD Preparative Regimen;   Drug: Osteopetrosis Only Preparative Regimen;   Drug: Osteopetrosis Haploidentical Only Preparative Regimen;   Drug: cALD SR-A (Standard-Risk, Regimen A);   Drug: cALD SR-B (Standard-Risk, Regimen B);   Drug: cALD HR-D (High-Risk, Regimen C);   Drug: cALD HR-D (High-Risk, Regimen D)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified June 2017

  • Condition:   Bilateral Severe to Profound Hearing Loss
    Intervention:   Drug: CGF166
    Sponsor:   Novartis Pharmaceuticals
    Recruiting - verified April 2017

  • Conditions:   Hearing Impairment;   Hearing Aid Fitting
    Intervention:   Device: mild-gain hearing aids
    Sponsor:   VA Office of Research and Development
    Recruiting - verified April 2017

  • Condition:   Severe Unilateral Sensorineural Hearing Loss
    Intervention:   Device: Cochlear implant
    Sponsor:   Mayo Clinic
    Recruiting - verified May 2017

  • Conditions:   Neuroectodermal Tumors, Primitive;   Liver Neoplasms;   Neoplasms, Germ Cell and Embryonal;   Osteosarcoma;   Other Childhood Cancers Using Cisplatin-based Regimens
    Intervention:   Drug: N-Acetylcysteine
    Sponsor:   Children's Hospital Los Angeles
    Recruiting - verified October 2016

  • Conditions:   Profound Bilateral Deafness Due to;   Bilateral Cochlear Aplasia;   Bilateral Cochlear Nerve Deficiency;   Bilateral Cochlear Ossification Secondary to Meningitis
    Intervention:   Device: Auditory Brainstem Implant
    Sponsors:   Laurie Eisenberg;   Keck School of Medicine of USC;   Children's Hospital Los Angeles;   Huntington Medical Research Institutes
    Recruiting - verified March 2017

  • Conditions:   Autism Spectrum Disorders;   Normal Hearing;   Normal Intelligence;   Exhibit Self- Stimulating or Ritualistic Behaviors
    Intervention:   Device: ProFoveate
    Sponsor:   University of Arkansas
    Recruiting - verified September 2016

  • Conditions:   Cisplatin Ototoxicity;   Hearing Loss
    Interventions:   Other: COMP-VA;   Other: Standard of care;   Other: Program evaluation
    Sponsor:   VA Office of Research and Development
    Recruiting - verified April 2017

  • Conditions:   Sensorineural Hearing Loss;   Long QT Syndrome
    Intervention:  
    Sponsor:   Mednax Center for Research, Education and Quality
    Recruiting - verified December 2016

  • Condition:   Bilateral Sensorineural Hearing Loss
    Intervention:   Device: Cochlear implant
    Sponsors:   American Cochlear Implant Alliance;   University of Michigan;   University of Iowa;   Johns Hopkins University;   University of Miami;   New York University School of Medicine;   University of North Carolina;   University of Southern California;   Vanderbilt University;   University of Washington;   Washington University School of Medicine;   Loyola University Chicago;   University of Pennsylvania;   University of Texas;   Saint Luke's Health System
    Recruiting - verified June 2017

  • Condition:   Noise-induced Hearing Loss
    Interventions:   Drug: Zonisamide;   Drug: Methylprednisolone
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified November 2016

  • Conditions:   Hearing Loss;   Tinnitus
    Interventions:   Other: Screening;   Other: Brochure;   Behavioral: Education
    Sponsor:   University of California, San Francisco
    Recruiting - verified May 2017

  • Condition:   Congenital Hearing Loss
    Interventions:   Behavioral: Patient Navigator;   Behavioral: Standard scheduling and follow-up
    Sponsors:   Matthew Bush, MD;   National Institute on Deafness and Other Communication Disorders (NIDCD);   National Institutes of Health (NIH)
    Recruiting - verified October 2016

  • Condition:   Bilateral Hearing Loss for Causes Other Than Tumors
    Intervention:   Device: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
    Sponsor:   Massachusetts Eye and Ear Infirmary
    Recruiting - verified April 2017

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated
    Recruiting - verified September 2016

  • Condition:   Sensorineural Hearing Loss
    Intervention:  
    Sponsor:   Steward St. Elizabeth's Medical Center of Boston, Inc.
    Recruiting - verified November 2016

  • Condition:   Bilateral Hearing Loss for Causes Other Than Tumors
    Intervention:   Device: Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)
    Sponsor:   Massachusetts Eye and Ear Infirmary
    Recruiting - verified April 2017

  • Conditions:   Presbycusis;   Aging;   Hearing Loss
    Intervention:   Device: hearing aid
    Sponsors:   Indiana University;   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified June 2017

  • Conditions:   Congenital Cytomegalovirus;   Hearing Loss
    Interventions:   Drug: Valcyte (Valganciclovir hydrochloride) Powder for oral solution;   Drug: Placebo
    Sponsor:   University of Alabama at Birmingham
    Recruiting - verified May 2017

  • Condition:   Healthy Volunteer
    Intervention:  
    Sponsor:   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified April 4, 2017

  • Conditions:   Usher Syndrome;   Retinitis Pigmentosa
    Intervention:   Genetic: UshStat
    Sponsor:   Sanofi
    Recruiting - verified March 2017

  • Conditions:   Neurofibromatosis Type 2;   Neuroma, Acoustic
    Intervention:   Drug: RAD001, everolimus
    Sponsors:   Jonsson Comprehensive Cancer Center;   Novartis Pharmaceuticals
    Recruiting - verified April 2017

  • Conditions:   Vestibular Schwannoma;   Acoustic Neuroma
    Intervention:   Radiation: Fractionated proton radiation
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting - verified July 2017

  • Condition:   Tinnitus
    Interventions:   Device: Repetitive Transcranial Magnetic Stimulation (rTMS) - ACTIVE;   Device: Repetitive Transcranial Magnetic Stimulation (rTMS) - SHAM
    Sponsors:   University of Arkansas;   National Institutes of Health (NIH)
    Recruiting - verified November 2016

  • Conditions:   Craniosynostosis;   Muenke Syndrome
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting - verified June 1, 2017

  • Conditions:   Sensorineural Hearing Loss;   Hearing Disorder;   Vestibular Disease
    Intervention:  
    Sponsor:   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified May 2, 2017

  • Conditions:   Sensorineural Hearing Loss;   Cytomegalovirus Infection
    Intervention:  
    Sponsor:   National Institute on Deafness and Other Communication Disorders (NIDCD)
    Recruiting - verified July 27, 2017